Search - tctmd.com

Displaying 341 - 360 of 379

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

Ashley Lyles

July 24, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Shelley Wood

March 09, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Conference News AHA 2016

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Yael L. Maxwell

November 29, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for October 2017

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

TCTMD’s Top 10 Most Popular Stories for August 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content